-
A WEEK-IN-REVIEW FEATURED REPORT
CONFERENCE PRESENTATION
Prognostic Factors of Virological
Success in Antiretroviral-naïve Patients Receiving LPV
Monotherapy
in the MONARK trial.
P Flandre, C Delaugerre, J Ghosn, et al
-
PDF
POSTER
Comparing the cost-effectiveness of
first-line HAART regimens
D Bishai, S Haberlen, L Spacek, MD, et al
-
PDF
POSTER
Single Agent Therapy (SAT) with
Lopinavir/ritonavir (LPV/r) Controls HIV-1 Viral Replication
in the Female Genital Tract
RF Yeh, HA Hammill, SA Fiscus, et al
-
PDF
POSTER
Achieving and Maintaining
Undetectable HIV-1 RNA: The Role of Adherence
RA Rode, BC Vrijens, P Kristanto, et al
-
PDF
POSTER
CD4+ T-cell Response to
Lopinavir/ritonavir-based Therapy in Antiretroviral-naïve HIV-1 Infected
Subjects: The Role of Adherence
RA Rode, TJ Podsadecki, GJ Hanna,
et al
-
PDF
POSTER
Safety of Kaletra as
Initial Therapy: A Combined Analysis of Phase II and III Clinical Trials
L Fredrick, WC Woodward, R Stryker, et al
-
A WEEK-IN-REVIEW FEATURED REPORT
CONFERENCE
PRESENTATION
Lopinavir/ritonavir monotherapy
versus lopinavir/ritonavir and two nucleosides for maintenance
therapy of HIV. Ninety-six week
results of a randomized, controlled, open-label clinical trial
(OK04 Study).
JR Arribas, F Pulido, R Delgado , et al
PDF
POSTER
Lopinavir/Ritonavir (LPV/r) 100/25
mg Tablet Developed for Pediatric Use: Bioequivalence to the
LPV/r 200/50 mg Tablet at a Dose of 400/100 mg and Predicted Dosing
Regimens in Children
CE. Klein, YL Chiu, SK Causemaker, et al
|
